Half-Year 2022 Financial and Clinical Trials Update

PRED infectious diseases development programs Roche Molecule Indication Phase # of patients Status CT Identifier Infectious Diseases FPI Q4 2016 TLR7 agonist (3) (RG7854) Chronic hepatitis B | 150 NCT02956850 Data presented at APASL 2019 FPI Q4 2016 1/11 192 NCT02952924 Data presented at EASL 2018, 2019 & 2020 CPAM (RG7907) Chronic hepatitis B FPI Q1 2021 22 NCT04729309 Recruitment completed Q2 2021 TLR7 agonist (3)/ CPAM/siRNA/ PDL1 LNA Chronic hepatitis B || 275 FPI Q3 2020 (RG7854/RG7907/RG6346/RG6084) PDL1 LNA (RG6084) Chronic hepatitis B Abx MCP (RG6006) A. baumannii infections Abx MCP-antibiotic macrocyclic peptide FPI Q1 2019 35 Part la: completed Part lb: initiated 204 FPI Q4 2020 NCT04225715 (PIRANGA) NCT04605718 155

View entire presentation